A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Public ClinicalTrials.gov record NCT06780137. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer
Study identification
- NCT ID
- NCT06780137
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 262 participants
Conditions and interventions
Conditions
Interventions
- Durvalumab Biological
- Gocatamig Biological
- Ifinatamab Deruxtecan (I-DXd) Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 26, 2025
- Primary completion
- Aug 30, 2029
- Completion
- Jan 16, 2030
- Last update posted
- Apr 19, 2026
2025 – 2030
United States locations
- U.S. sites
- 9
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado Anschutz Medical Campus ( Site 1110) | Aurora | Colorado | 80045 | Recruiting |
| University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1111) | Miami | Florida | 33136 | Recruiting |
| University of Chicago ( Site 1108) | Chicago | Illinois | 60637 | Recruiting |
| Dana Farber Cancer Institute ( Site 1105) | Boston | Massachusetts | 02215 | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103) | Hackensack | New Jersey | 07601 | Recruiting |
| Roswell Park Cancer Institute ( Site 1107) | Buffalo | New York | 14263 | Recruiting |
| Providence Portland Medical Center ( Site 1101) | Portland | Oregon | 97213 | Recruiting |
| Sarah Cannon Research Institute ( Site 7001) | Nashville | Tennessee | 37203 | Recruiting |
| Medical College of Wisconsin ( Site 1112) | Milwaukee | Wisconsin | 53226 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06780137, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06780137 live on ClinicalTrials.gov.